Miranda-G E, Ostrosky-Wegman P

Language: Spanish
References: 41
Page: 59-63
PDF size: 63.13 Kb.

ABSTRACT

Pharmacogenetics originated from the clinical observation that there were individual differences in drug response. Different patients response to the same drug in different ways, showing differences in efficacy and toxicity. Most drug effects are determined by the interplay of the genes that influence the pharmacokinetics and pharmacodynamics of medications. Once a drug is absorbed, it undergoes metabolism and there are inherited variations in drug metabolism. The cytochrome P450, a superfamily of microsomal drug-metabolizing enzymes carries 40% of drug metabolism and one of its members CYP2D6 has been shown to be responsible of the different responses observed during the treatments with analgesic, antiarrhytmic, antidepressant, antipsychotic, anticonvulsive and antihistaminic drugs. The CYP2D6 polymorphism represents an excellent example of how pharmacogenetic research led from knowing the phenotype to the understanding of the genotype. It is also a good example of the clinical implications of pharmacogenetics in the scientific understanding of individual variation in drug response and in the great potential to identify the right medicine and dose for each patient.

REFERENCES

1. Nebert DW, Nelson DR, Adesnik M, Coon MJ, Estabrook RW, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF, Kemper B, Levin W, Phillips IR, Sato R, Waterman MR. The P450 superfamily: updated listing of all genes and recommended nomenclature for the chromosomal loci. DNA 1989; 8: 1-13.

2. Lewis DFV. Cytochromes P450 Structure and Function. Taylor & Francis, New York, 2001.

3. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet. 2002; 360: 1155-1162.

4. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalas IC, Nebert DW. Cytochrome P450 superfamily: update on new sequences, gene mapping, accession numbers, and nomenclature. Pharmacogenetics 1996; 6: 1-42.

5. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32: 210-258.

6. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988; 331: 442-446.

7. Eichelbaum M, Baur MP, Dengler HJ, Osikowska-Evers BO, Tieves G, Zekorn C. Chromosomal assignment of human cytochrome P450 (debrisoquine/sparteine type) to chromosome 22. Brit J Pharm 1987; 23: 455-458.

8. Gough AC, Smith CA, Howell SM, Wolf CR, Bryant SP, Spurr NK. Localization of the CYP2d gene locus to human chromosome 22q13.1 by polymerase chain reaction, in situ hybridization, and linkage analysis. Genomics 1993; 15: 430-432.

9. Niznik HB, Tyndale RF, Salle FR, Gonzalez FJ, Hardwick JP, Inaba T, Kalow W. The dopamine transporter and cytochrome P450Iid1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins. Arch Biochem Biophys 1990; 276: 424-432.

10. Romkes-Sparks M, Mnuskin A, Chern HD, Persad R, Fleming C, Sibley GN, Smith P, Wilkinson GR, Branch RA. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity. Carcinogenesis 1994; 15: 1955-1961.

11. Carcillo JA, Parise RA, Adedoyin A, Frye R, Branch RA, Romkes M. CYP2D6 mRNA expression in circulating peripheral blood mononuclear cells correlates with in vivo debrisoquine hydroxylase activity in extensive metabolizers. Res Commun Mol Pathol Pharmacol 1996; 91: 149-159.

12. Hakkola J, Raunio H, Purkunen R, Pelkonen O, Saarikoski S, Cresteil T, Pasanen M. Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy. Biochem Pharmacol 1996; 52: 379-383.

13. Guidice JM, Marez D, Sabbagh N, Legrand-Andreoletti M, Spire C, Alcaide E Lafitte JJ, Broly F, Matsunaga T. Evidence for CYP2D6 expression in human lung. Biochem Biophys Res Commun 1997; 241: 79-85.

14. Huang Z, Fasco MJ, Kaminsky LS. Alternative splicing of CYP2D mRNA in human breast tissue. Arch Biochem Biophys 1997; 343: 101-108.

15. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; II: 584-586.

16. Idle JR, Mahgoub A, Lancaster R, Smith RL. Hypotensive response to debrisoquine and hydroxylation phenotype. Life Sci 1978; 22: 979-984.

17. Dahl ML, Johansson I, Bertilson L. Ultra-rapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. JPET 1995; 274: 516-520.

18. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelamn-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Nat Acad Sci 1993; 90: 11825-11829.

19. Dalen P, Dahl ML, Ruiz MLE, Nordin J, Bertilsson L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3 and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998; 63: 444-452.

20. Tyndale RF, Droll KP, Sellers EM. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependance. Pharmacogenetics 1997; 7: 375-379.

21. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356: 1667-1671.

22. Kroemer HK, Eichelbaum M. Molecular basis and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 1995; 56: 2285-2298.

23. Nebert DW. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet 1997; 60: 265-271.

24. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284-295.

25. West WL, Knight EM, Pradhan S, Hinds TS. Interpatient variability: genetic predisposition and other genetic factors. J Clin Pharmacol 1997; 37: 635-648.

26. Eichelbaum M, Evans W, Yamazoe Y. A tribute to Frank Gonzalez Pharmacogenetics 2001; 11: 371.

27. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA. Two mutant alleles of the human cytochrome P-450db1 gene(P450c2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 1988; 85: 5240-5243.

28. Evans WE, Relling MV. Xbal 16-plus 9-kilobase DNA restriction fragments identify a mutant allele for debrisoquin hydroxylase: report of a family study. Mol Pharmacol 1990; 37: 639-642.

29. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991; 48: 943-950.

30. Hanioka N, Kimura S, Meyer UA, Gonzalez FJ. The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3’ splice recognition site. Am J Hum Genet 1990; 47: 994-1001.

31. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 1990; 265: 17209-17214.

32. Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 1990; 347: 773-776.

33. Saxena R, Shaw GL, Relling MV, Frame JN, Moir DT, Evans WE, Caporaso N, Weiffenbach B. Identification of anew variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Hum Mol Genet 1994; 3: 923-926.

34. Yamazaki H, Kiyotani K, Tsubuku S. Two novel haplotypes of CYP2D6 gene in a japanese population. Drug Metab Pharmacokin 2003; 18(4): 269-271.

35. Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white british population. J Med Genet 1980; 17: 102-105.

36. Kalow W. The metaboilsm of xenobiotics in different populations. Canad J Physiol Pharm 1982; 60: 1-12.

37. Zhou HH, Koshakji RP, Silberstein DJ, Wilkinson GR, Wood AJJ. Racial Differences in drug reponse: altered sensitivity to and clearance of propanolol in men of chinese descente as compared with American whites. New Engl J Med 1989; 320: 565-570.

38. Gonzalez FJ, Nebert DW. Evolution of the P450 gene superfamily. Trends in Genetics 1990; 6: 182-186.

39. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment. Trens Pharmacol Sci 1999; 20: 342-349.

40. Murphy MP, Beaman ME, Clark LS. Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial. Pharmacogenomics 2000; 10: 583-590.

41. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hidroxylase (CYP2D) locus: sequence ad identification of the polymorphic CYP2D6 gene, a related gene, and pseudogene. Am J Hum Genet 1989; 45: 889-904.